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BRCA1 on the move
T
he E3 ubiquitin ligase BRCA1 is 
a tumor suppressor best known 
for its role in DNA damage repair. 
Coene et al. report a new function for the 
protein, revealing that it also operates at the 
leading edge and at focal adhesions to regu-
late cell spreading and motility (1).
Mutations in BRCA1 are associated 
with familial forms of breast and ovarian 
cancer. How the protein protects cells from 
carcinogenesis is unclear, though most of 
its known functions—including transcrip-
tional regulation and DNA double-strand 
break repair—occur in the nucleus (2). In 
2005, David Vaux and colleagues from the 
University of Oxford, UK, and the Univer-
sity of Ghent, Belgium, demonstrated that 
BRCA1 also localizes to mitochondria, 
where it presumably maintains the integrity 
of mitochondrial DNA (3).
Following up on this discovery, Vaux 
and co-workers set out to identify proteins 
that bind to BRCA1’s C terminus—a region 
required for the protein’s tumor-suppressive 
activity. “We were looking for proteins that 
might have a role in BRCA1’s mitochon-
drial import,” Vaux recounts. “We found a 
good candidate [that we’re working on at 
the moment]. But we also found members 
of the ezrin, radixin, and moesin (ERM) 
family, which was completely unexpected.”
ERM proteins link the plasma mem-
brane to the underlying actin cytoskeleton 
(4). Coene et al. saw that 
BRCA1 colocalized with 
ERM proteins and F-actin 
in both plasma membrane 
ruffl  es and focal adhesions. 
To determine whether 
BRCA1 had any function at 
these locations, the re-
searchers used a C-terminal 
fragment of the protein that displaced endog-
enous BRCA1 from the plasma membrane.
Cells overexpressing this dominant-neg-
ative construct spread more slowly after 
plating on adhesive surfaces and showed 
increased motility compared with control 
cells. Moreover, human breast cancer cells 
with mutations in BRCA1 moved faster 
than breast cancer lines with an intact 
BRCA1 gene. Re-introducing wild-type 
BRCA1 reversed this increase in motility, 
but a mutant version of the protein that 
lacked ubiquitin ligase activity was unable 
to restore migration to normal speed. “This 
suggests that BRCA1 not only needs to be 
at the cell periphery but that it also has to be 
active when it’s there,” says Vaux.
Coene et al. used an in vitro scratch-
wound assay to assess whether the increased 
migration of cells lacking BRCA1 had any 
functional consequences. 
Cells expressing the BRCA1 
C-terminal dominant-nega-
tive fragment closed the 
wound at the same rate as 
control cells, but video mi-
croscopy revealed that they 
behaved very differently as 
they did so. “Control cells 
close the wound almost like a curtain. Cells 
at the wound edge remain in contact with 
cells further back in the monolayer,” Vaux 
explains. “But cells overexpressing the 
BRCA1 C-terminal domain fi  ll the wound 
with individual cells that have no contact 
with the leading edge.”
The decrease in intercellular adhesion 
and increase in motility suggest that loss of 
BRCA1 may make tumor cells more likely 
to metastasize. Indeed, some studies have 
found that BRCA1 expression is lower in 
metastatic deposits than in primary tumors. 
“In the longer term, we want to look at mu-
rine models of metastasis with different lev-
els of BRCA1 at the cell periphery,” Vaux 
says. “The protein might regulate the migra-
tion of cells from a variety of solid tumors.”
In the shorter term, however, Vaux’s 
goal is to identify targets of BRCA1’s 
ubiquitin ligase activity and to determine 
how they affect adhesion and migration. 
Vaux explains: “I think of BRCA1 as a 
timer for assembling and stabilizing com-
plexes in particular places. The ability of 
BRCA1 to ubiquitinate and stabilize DNA 
repair complexes at double-strand breaks 
may turn out to be similar to its function at 
the cell periphery, where it might, for ex-
ample, orchestrate a complex that modu-
lates integrin availability.”
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Elisabeth Coene (left), David Vaux (right), and colleagues (not shown) reveal that the tumor 
suppressor and E3 ubiquitin ligase BRCA1 is targeted to the cell periphery by ezrin, radixin, and 
moesin proteins, where it regulates cell adhesion and migration. Compared with control cells (top), 
cells expressing a dominant-negative version of BRCA1 (bottom) migrate faster but close wounds 
in a more disorganized fashion, as individual cells lose contact with their neighbors. The ﬁ  ndings 
suggest that BRCA1 ubiquitinates proteins involved in cell–cell and cell–matrix adhesion and that 
the tumor suppressor may also limit the ability of cancer cells to metastasize.
“[BRCA1] might 
regulate the 
migration of cells 
from a variety of 
solid tumors.”
The tumor suppressor functions outside the nucleus to regulate cell adhesion and migration.
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